CHMP besluttede derfor, at fordelene ved IONSYS er større end risiciene til behandling af akut, moderat til svær smerte efter operation udelukkende i hospitalsomgivelser.
Therefore, the Committee decided that IONSYS’ s benefits are greater than its risks for the management of acute moderate to severe post-operative pain for use in a hospital setting only.